Investigational drug · Phase 2
AZD5851
Also called: Cell Therapy
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AZD5851"
First trial start
2023
Dec 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5851", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5851" as an intervention, largest first.
- A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06084884 · 94 participants (planned) · Start Dec 14, 2023 · Primary completion Dec 13, 2027
Drug: AZD5851 · For: Hepatocellular Carcinoma
Sites: Phoenix, Arizona; Duarte, California; Los Angeles, California · 19 sites in all
- LTFU for All Cell and Gene Therapy StudiesNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT06194461 · 64 participants (planned) · Start Sep 17, 2025 · Primary completion Nov 29, 2041
Drug: AZD5851; AZD0754 · For: Hepatocellular Carcinoma; Prostate Cancer
Sites: Phoenix, Arizona; Duarte, California; Orange, California · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Spatial mechanopriming of multicellular interfaces drives cytoskeletal-to-nuclear remodeling to boost therapeutic efficacy of stem cells.
Bayaraa O, Lee NH, Kim SH, et al. · Bioact Mater 2027
- DNA-adsorbing nanozyme hydrogel reprograms the immuno-oxidative microenvironment to support stem cell-based cartilage repair in osteoarthritis.
Yu H, Hu Z, Tan Q, et al. · Bioact Mater 2027
- Genetically engineering mast cells as effectors for targeted cancer cell cytotoxicity.
Han X, Wen D, Fu R, et al. · Biomaterials 2027
- A Novel Multi-Modality Approach to Skin Rejuvenation: Integrating Systemic Optimization, Nitric Oxide Priming, Placental Exosomes, Dermoelectroporation, and Injectable Biologic Scaffolds.
Chernoff G · Facial Plast Surg Clin North Am 2027
- Stromal Cells and Sjögren's Disease.
McCoy SS, Manfrè V · Rheum Dis Clin North Am 2027
- In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions.
Zhao Y, Liu Y, Peng X, et al. · Genes Dis 2027
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.